Miguel Gonzalez Velez, MD, discusses the role of tarlatamab as a second-line treatment for small cell lung cancer.
Miguel Gonzalez Velez, MD
Advertisement
Miguel Gonzalez Velez, MD, is a Thoracic Oncologist and member of the Drug Discovery/Phase I Research at Hackensack University Medical Center & John Theurer Cancer Center.
Articles by Miguel Gonzalez Velez, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma
2
PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer
3
Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma
4
Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer
5